Tyrosinemia: Difference between revisions

From WikiMD's Medical Encyclopedia

CSV import
 
CSV import
 
(2 intermediate revisions by the same user not shown)
Line 1: Line 1:
'''Tyrosinemia''' is a group of rare genetic disorders characterized by disruptions in the metabolic pathway of the amino acid tyrosine. This results in an accumulation of tyrosine and its by-products in the body, leading to a variety of health problems. There are three types of tyrosinemia, each with distinct symptoms and treatment options.
{{SI}}
 
{{Infobox medical condition
==Types of Tyrosinemia==
| name            = Tyrosinemia
There are three types of tyrosinemia, each caused by the deficiency of a different enzyme involved in the metabolic pathway of tyrosine.
| image          = [[File:L-tyrosine-skeletal.png|left|thumb|L-Tyrosine]]
 
| caption        = L-Tyrosine, the amino acid involved in tyrosinemia
===Tyrosinemia Type I===
| field          = [[Medical genetics]]
[[Tyrosinemia Type I]] is the most severe form of the disorder. It is caused by a deficiency of the enzyme fumarylacetoacetate hydrolase (FAH). Symptoms usually appear in the first few months of life and include failure to gain weight and grow at the expected rate (failure to thrive), diarrhea, vomiting, yellowing of the skin and whites of the eyes (jaundice), and a cabbage-like odor.
| symptoms        = [[Failure to thrive]], [[vomiting]], [[diarrhea]], [[jaundice]], [[hepatomegaly]], [[renal tubular dysfunction]]
 
| complications  = [[Liver failure]], [[renal failure]], [[neurological crises]], [[hepatocellular carcinoma]]
===Tyrosinemia Type II===
| onset          = Infancy or early childhood
[[Tyrosinemia Type II]], also known as Richner-Hanhart syndrome, is caused by a deficiency of the enzyme tyrosine aminotransferase (TAT). Symptoms can include painful skin lesions on the palms and soles, eye abnormalities, and intellectual disability.
| duration        = Lifelong
 
| types          = Type I (hepatorenal), Type II (oculocutaneous), Type III (neurological)
===Tyrosinemia Type III===
| causes          = [[Genetic mutation]] in [[FAH]], [[TAT]], or [[HPD]] genes
[[Tyrosinemia Type III]] is the rarest form of the disorder and is caused by a deficiency of the enzyme 4-hydroxyphenylpyruvate dioxygenase (HPD). Symptoms can include intellectual disability, seizures, and periodic loss of balance and coordination (ataxia).
| risks          = [[Consanguinity]], [[family history]]
 
| diagnosis      = [[Blood test]], [[urine test]], [[genetic testing]]
| differential    = [[Galactosemia]], [[hereditary fructose intolerance]], [[citrullinemia]]
| treatment      = [[Dietary restriction]], [[nitisinone]], [[liver transplantation]]
| medication      = [[Nitisinone]]
| prognosis      = Variable, depends on type and treatment
| frequency      = Rare
}}
{{Short description|A genetic disorder affecting tyrosine metabolism}}
[[File:Inborn_errors_of_metabolism_of_phenylalanine_and_tyrosine.svg|Diagram showing inborn errors of metabolism related to phenylalanine and tyrosine|thumb|left]]
'''Tyrosinemia''' is a genetic disorder characterized by elevated levels of the amino acid [[tyrosine]] in the blood. This condition is caused by a deficiency in one of the enzymes responsible for the breakdown of tyrosine, leading to its accumulation and associated health problems.
==Types==
There are three main types of tyrosinemia, each caused by a deficiency in a different enzyme involved in tyrosine metabolism:
* '''Tyrosinemia type I''' (hepatorenal tyrosinemia) is the most severe form and is caused by a deficiency of the enzyme fumarylacetoacetate hydrolase (FAH). This type can lead to liver and kidney failure, as well as neurological problems.
* '''Tyrosinemia type II''' (oculocutaneous tyrosinemia) is caused by a deficiency of the enzyme tyrosine aminotransferase (TAT). It primarily affects the eyes, skin, and mental development.
* '''Tyrosinemia type III''' is the rarest form and is caused by a deficiency of the enzyme 4-hydroxyphenylpyruvate dioxygenase (HPD). It can lead to neurological problems.
==Genetics==
[[File:Autorecessive.svg|left|thumb|Tyrosinemia is inherited in an autosomal recessive pattern.]]
Tyrosinemia is inherited in an [[autosomal recessive]] pattern, meaning that an individual must inherit two copies of the defective gene, one from each parent, to be affected by the disorder. Carriers, who have only one copy of the mutated gene, typically do not show symptoms.
==Pathophysiology==
[[File:Inborn_errors_of_metabolism_of_phenylalanine_and_tyrosine.svg|left|thumb|Inborn errors of metabolism of phenylalanine and tyrosine]]
The accumulation of tyrosine and its metabolites in the body can lead to a variety of symptoms and complications, depending on the type of tyrosinemia. In type I, the accumulation of toxic metabolites can cause severe liver and kidney damage. In type II, the buildup of tyrosine affects the eyes and skin, while in type III, neurological issues are more prominent.
==Diagnosis==
==Diagnosis==
Diagnosis of tyrosinemia is based on the presence of characteristic symptoms, a detailed patient history, a thorough clinical evaluation, and a variety of specialized tests. These tests can include blood and urine tests, genetic testing, and liver biopsy.
Diagnosis of tyrosinemia is typically made through blood and urine tests that measure the levels of tyrosine and its metabolites. Genetic testing can confirm the specific enzyme deficiency and type of tyrosinemia.
 
==Treatment==
==Treatment==
Treatment of tyrosinemia is aimed at managing the symptoms and preventing complications. This can include a low-protein diet, medications, and in some cases, liver transplantation.
Treatment for tyrosinemia varies depending on the type but often includes dietary restrictions to limit tyrosine intake. For type I, the drug nitisinone (NTBC) is used to block the formation of toxic metabolites. Liver transplantation may be necessary in severe cases.
 
==Prognosis==
==See Also==
With early diagnosis and appropriate treatment, individuals with tyrosinemia can lead relatively normal lives. However, untreated tyrosinemia, especially type I, can lead to severe complications and reduced life expectancy.
* [[Amino acid metabolism disorder]]
==See also==
* [[Genetic disorder]]
* [[Phenylketonuria]]
* [[Metabolic disorder]]
* [[Alkaptonuria]]
 
* [[Maple syrup urine disease]]
[[Category:Genetic disorders]]
==References==
[[Category:Metabolic disorders]]
{{Reflist}}
[[Category:Rare diseases]]
[[Category:Inborn errors of metabolism]]
 
[[Category:Autosomal recessive disorders]] {{stub}}
{{stub}}

Latest revision as of 23:12, 6 April 2025

Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD's medical weight loss NYC, sleep center NYC
Philadelphia medical weight loss and Philadelphia sleep clinics

Tyrosinemia
L-Tyrosine
Synonyms N/A
Pronounce N/A
Specialty N/A
Symptoms Failure to thrive, vomiting, diarrhea, jaundice, hepatomegaly, renal tubular dysfunction
Complications Liver failure, renal failure, neurological crises, hepatocellular carcinoma
Onset Infancy or early childhood
Duration Lifelong
Types Type I (hepatorenal), Type II (oculocutaneous), Type III (neurological)
Causes Genetic mutation in FAH, TAT, or HPD genes
Risks Consanguinity, family history
Diagnosis Blood test, urine test, genetic testing
Differential diagnosis Galactosemia, hereditary fructose intolerance, citrullinemia
Prevention N/A
Treatment Dietary restriction, nitisinone, liver transplantation
Medication Nitisinone
Prognosis Variable, depends on type and treatment
Frequency Rare
Deaths N/A


A genetic disorder affecting tyrosine metabolism


Diagram showing inborn errors of metabolism related to phenylalanine and tyrosine

Tyrosinemia is a genetic disorder characterized by elevated levels of the amino acid tyrosine in the blood. This condition is caused by a deficiency in one of the enzymes responsible for the breakdown of tyrosine, leading to its accumulation and associated health problems.

Types[edit]

There are three main types of tyrosinemia, each caused by a deficiency in a different enzyme involved in tyrosine metabolism:

  • Tyrosinemia type I (hepatorenal tyrosinemia) is the most severe form and is caused by a deficiency of the enzyme fumarylacetoacetate hydrolase (FAH). This type can lead to liver and kidney failure, as well as neurological problems.
  • Tyrosinemia type II (oculocutaneous tyrosinemia) is caused by a deficiency of the enzyme tyrosine aminotransferase (TAT). It primarily affects the eyes, skin, and mental development.
  • Tyrosinemia type III is the rarest form and is caused by a deficiency of the enzyme 4-hydroxyphenylpyruvate dioxygenase (HPD). It can lead to neurological problems.

Genetics[edit]

Tyrosinemia is inherited in an autosomal recessive pattern.

Tyrosinemia is inherited in an autosomal recessive pattern, meaning that an individual must inherit two copies of the defective gene, one from each parent, to be affected by the disorder. Carriers, who have only one copy of the mutated gene, typically do not show symptoms.

Pathophysiology[edit]

Inborn errors of metabolism of phenylalanine and tyrosine

The accumulation of tyrosine and its metabolites in the body can lead to a variety of symptoms and complications, depending on the type of tyrosinemia. In type I, the accumulation of toxic metabolites can cause severe liver and kidney damage. In type II, the buildup of tyrosine affects the eyes and skin, while in type III, neurological issues are more prominent.

Diagnosis[edit]

Diagnosis of tyrosinemia is typically made through blood and urine tests that measure the levels of tyrosine and its metabolites. Genetic testing can confirm the specific enzyme deficiency and type of tyrosinemia.

Treatment[edit]

Treatment for tyrosinemia varies depending on the type but often includes dietary restrictions to limit tyrosine intake. For type I, the drug nitisinone (NTBC) is used to block the formation of toxic metabolites. Liver transplantation may be necessary in severe cases.

Prognosis[edit]

With early diagnosis and appropriate treatment, individuals with tyrosinemia can lead relatively normal lives. However, untreated tyrosinemia, especially type I, can lead to severe complications and reduced life expectancy.

See also[edit]

References[edit]

This article is a medical stub. You can help WikiMD by expanding it!
PubMed
Wikipedia